SS
MTNB icon

SBI Securities’s Matinas BioPharma MTNB Stock Holding History

SBI Securities’s Portfolio MTNB Stock Details MTNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7 Buy
12
+1
+9% +$1 ﹤0.01% 3947
2026
Q1 		$6 Hold
11
– – ﹤0.01% 3900
2025
Q4 		$6 Hold
11
– – ﹤0.01% 3920
2025
Q3 		$21 Hold
11
– – ﹤0.01% 3911
2025
Q2 		$10 Sell
11
-2
-15% -$1 ﹤0.01% 4012
2025
Q1 		$7 Buy
13
+2
+18% +$1 ﹤0.01% 4001
2024
Q4 		$6 Buy
+11
New +$17 ﹤0.01% 3980

Other funds holding MTNB

Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
HIW
Holos Integrated Wealth Kennett Square, Pennsylvania $214M AUM 14.99% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SIG
Sargent Investment Group Bethesda, Maryland $832M AUM 24.89% 1-Year Est. Return

SBI Securities's MTNB Position: Q2 2026 in Review

SBI Securities increased its Matinas BioPharma (MTNB) stake by 9.1% in Q2 2026, buying an estimated $1 and bringing the position to 12 shares worth $7. The position accounts for ﹤0.01% of the portfolio, ranked #3947.

SBI Securities first reported a position in MTNB in Q4 2024 and has held it in 7 quarters since. The position peaked at $21 in Q3 2025. 25 funds tracked by Wall St. Rank hold MTNB as of Q2 2026.

  • SBI Securities held 12 shares of Matinas BioPharma worth $7 as of Q2 2026.
  • SBI Securities bought 1 Matinas BioPharma share in Q2 2026, an estimated $1.
  • Matinas BioPharma made up ﹤0.01% of SBI Securities's portfolio in Q2 2026, its #3947 holding.
  • SBI Securities first reported a position in Matinas BioPharma in Q4 2024 and has held it in 7 quarters since.
  • SBI Securities's Matinas BioPharma position peaked at $21 in Q3 2025.
  • 25 funds tracked by Wall St. Rank held Matinas BioPharma as of Q2 2026.

Based on SBI Securities's 13F filing for Q2 2026, filed 23 Jul 2026.